NBIX - ニュ―ロクライン・バイオサイエンシズ (Neurocrine Biosciences Inc.)

NBIXのニュース

   Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)  2021/03/02 12:30:00 PR Newswire
SAN DIEGO, March 2, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced that investigational drug luvadaxistat (NBI-1065844/TAK-831) did not meet its primary endpoint in the Phase II INTERACT study in adults with negative symptoms of schizophrenia, as measured by…
   Malcolm Lloyd-Smith Sells 865 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock  2021/02/11 12:00:41 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Malcolm Lloyd-Smith sold 865 shares of the firm’s stock in a transaction on Friday, February 5th. The stock was sold at an average price of $114.15, for a total value of $98,739.75. Following the sale, the insider now owns 29,675 shares in the company, valued at approximately $3,387,401.25. The transaction […]
   Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $275,951.14 in Stock  2021/02/10 02:56:57 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,363 shares of the firm’s stock in a transaction on Monday, February 8th. The shares were sold at an average price of $116.78, for a total value of $275,951.14. Following the completion of the transaction, the insider now owns 17,231 shares of the company’s stock, valued at […]
   Neurocrine exits $165M Parkinson's pact with Voyager after FDA hold  2021/02/03 15:01:09 FierceBiotech
In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics. Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold.
   Neurocrine axes Parkinson's collab with Voyager after safety issues, jeopardizing biotech's long-running centerpiece  2021/02/02 22:07:11 Endpoints News
Six years ago, Third Rock Ventures launched Voyager Therapeutics with $45 million and a goal of bringing gene therapy into some of the most notorious neurological diseases, most notably Parkinson's. Now that program, long their lead and only clinical asset, is in jeopardy. Voyager announced Tuesday afternoon that Neurocrine Biosciences
   Neurocrine exits $165M Parkinson's pact with Voyager after FDA hold  2021/02/03 15:01:09 FierceBiotech
In one of the top biopharma licensing deals of 2019, Neurocrine Biosciences bet $165 million—and promised $1.7 billion more—on a gene therapy partnership with Voyager Therapeutics. Now, it’s pulling out of the Parkinson’s disease portion of the deal, thanks to safety issues that have led to an FDA clinical hold.
   Neurocrine axes Parkinson's collab with Voyager after safety issues, jeopardizing biotech's long-running centerpiece  2021/02/02 22:07:11 Endpoints News
Six years ago, Third Rock Ventures launched Voyager Therapeutics with $45 million and a goal of bringing gene therapy into some of the most notorious neurological diseases, most notably Parkinson's. Now that program, long their lead and only clinical asset, is in jeopardy. Voyager announced Tuesday afternoon that Neurocrine Biosciences
   Kevin Charles Gorman Sells 308,250 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock  2021/01/14 09:22:59 Watchlist News
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 308,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $110.22, for a total value of $33,975,315.00. Following the completion of the sale, the chief executive officer now owns 584,520 shares in […]
   Neurocrine Biosciences Announces Repurchase of Convertible Notes  2020/11/19 13:00:00 PR Newswire
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024…
   Neurocrine Biosciences Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 Benzinga
SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with tardive dyskinesia as possible and we are adapting to the challenges posed by the pandemic, including the slow recovery of in-person visits with psychiatrists. We are encouraged by recent trends and remain confident in the intermediate and long-term opportunity of INGREZZA to help many more patients with tardive dyskinesia," said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We are pleased to expand our reach with neurologists with the addition of ONGENTYS to our movement disorder portfolio and continue to advance our development programs focused on neurological, endocrine and psychiatric disorders." Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, (unaudited, in millions, except per share data) 2020 2019 2020 2019 Revenues: Product sales, net $ 254.
   Neurocrine Biosciences Announces Repurchase of Convertible Notes  2020/11/19 13:00:00 PR Newswire
SAN DIEGO, Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the Company has entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024…
   Neurocrine Biosciences Reports Third Quarter 2020 Financial Results  2020/11/09 21:01:00 Benzinga
SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial results for the third quarter ended September 30, 2020 and provided revised full-year 2020 financial expense guidance. "Our focus remains on helping as many patients with tardive dyskinesia as possible and we are adapting to the challenges posed by the pandemic, including the slow recovery of in-person visits with psychiatrists. We are encouraged by recent trends and remain confident in the intermediate and long-term opportunity of INGREZZA to help many more patients with tardive dyskinesia," said Kevin Gorman , Ph.D., Chief Executive Officer of Neurocrine Biosciences. "We are pleased to expand our reach with neurologists with the addition of ONGENTYS to our movement disorder portfolio and continue to advance our development programs focused on neurological, endocrine and psychiatric disorders." Financial Highlights Three Months Ended September 30, Nine Months Ended September 30, (unaudited, in millions, except per share data) 2020 2019 2020 2019 Revenues: Product sales, net $ 254.
   Neurocrine Biosciences to Present at Upcoming Healthcare Conferences  2020/11/09 14:00:00 PR Newswire
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Kevin Gorman, Chief Executive Officer, and Kyle Gano, Chief Business Development and Strategy…
   Neurocrine Biosciences Q3 2020 Earnings Preview (NASDAQ:NBIX)  2020/11/08 17:02:31 Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to announce Q3 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate i
   Biogen, UnitedHealth: 5 Top Stock Gainers for Wednesday  2020/11/04 18:03:11 The Street
Super Micro Computer, Biogen, Neurocrine Biosciences, Supernus Pharmaceuticals and UnitedHealth.

calendar